Stereochemistry | ABSOLUTE |
Molecular Formula | C12H17N3O4S |
Molecular Weight | 299.346 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CC(SCCNC=N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O
InChI
InChIKey=ZSKVGTPCRGIANV-ZXFLCMHBSA-N
InChI=1S/C12H17N3O4S/c1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17/h5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19)/t6-,7-,9-/m1/s1
Imipenem is a beta-lactam antibiotic belongings to the subgroup of carbapenems. Imipenem has a broad spectrum of activity against aerobic and anaerobic Gram positive as well as Gram negative bacteria. It is particularly important for its activity against Pseudomonas aeruginosa and the Enterococcus species. Imipenem is rapidly degraded by the renal enzyme dehydropeptidase when administered alone, and is always co-administered with cilastatin to prevent this inactivation. The bactericidal activity of imipenem results from the inhibition of cell wall synthesis. Its greatest affinity is for
penicillin binding proteins (PBPs) 1A, 1B, 2, 4, 5 and 6 of Escherichia coli, and 1A, 1B, 2, 4 and 5 of
Pseudomonas aeruginosa. The lethal effect is related to binding to PBP 2 and PBP 1B. Imipenem is marketed under the brand name Primaxin. PRIMAXIN I.M. (Imipenem and Cilastatin for Injectable Suspension) is a formulation of imipenem (a
thienamycin antibiotic) and cilastatin sodium (the inhibitor of the renal dipeptidase, dehydropeptidase I).
PRIMAXIN I.M. is a potent broad spectrum antibacterial agent for intramuscular administration.
Originator
Approval Year
Doses
AEs
Sourcing
PubMed
Patents
Sample Use Guides
PRIMAXIN I.M. (Imipenem and Cilastatin for Injection) is for intramuscular use only. Patients with lower respiratory tract infections, skin and skin structure infections, and gynecologic
infections of mild to moderate severity may be treated with 500 mg or 750 mg administered every
12 hours depending on the severity of the infection.
Intra-abdominal infection may be treated with 750 mg every 12 hours. Total daily IM dosages greater than 1500 mg per day are not recommended.
Route of Administration:
Intramuscular